We’re excited to announce that our president Jeffrey T. Apter is joining CINP-AsCNP 2025 next week!
We are proud to be a part of this meeting — it is a premier international event that brings together leading minds in neuropsychopharmacology and neuroscience.
Jeffrey’s attendance represents a unique opportunity to share insights, foster innovation, and contribute to advancing mental health research and treatment on a global scale. Jeffrey T. Apter oversees our neurology pipeline. With over 300 clinical trials conducted as a Principal Investigator, primarily in CNS, Dr. Apter brings extensive expertise in Depression, Anxiety Disorders, Bipolar Disorder, Schizophrenia, Epilepsy and Alzheimer’s Disease.
If you want to meet Jeffrey or if you are interested in more details regarding GCT’s experience in neurology, please, contact us at bd@gctrials.com.
See you in Melbourne 👋